J
James H.F. Rudd
Researcher at University of Cambridge
Publications - 185
Citations - 13398
James H.F. Rudd is an academic researcher from University of Cambridge. The author has contributed to research in topics: Positron emission tomography & Coronary artery disease. The author has an hindex of 54, co-authored 169 publications receiving 11277 citations. Previous affiliations of James H.F. Rudd include Mount Sinai Hospital & Cambridge University Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography
James H.F. Rudd,Elizabeth A. Warburton,Tim D. Fryer,Hazel A. Jones,John C. Clark,Nagui M. Antoun,Peter Johnström,Anthony P. Davenport,Peter J. Kirkpatrick,B.N. Arch,John D. Pickard,P. L. Weissberg +11 more
TL;DR: It is demonstrated that atherosclerotic plaque inflammation can be imaged with 18 FDG-PET, and that symptomatic, unstable plaques accumulate more 18FDG than asymptomatic lesions.
Journal ArticleDOI
18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial
Nikhil Joshi,Alex T. Vesey,Michelle C. Williams,Anoop S V Shah,Patrick A. Calvert,Felicity H. Craighead,Su Ern Yeoh,William Wallace,Donald Salter,Alison Fletcher,Edwin J R van Beek,Andrew D. Flapan,Neal G. Uren,Miles Behan,Nicholas L. Cruden,Nicholas L. Mills,Keith A.A. Fox,James H.F. Rudd,Marc R. Dweck,David E. Newby +19 more
TL;DR: 18)F-NaF PET-CT is the first non-invasive imaging method to identify and localise ruptured and high-risk coronary plaque and is needed to establish whether this method can improve the management and treatment of patients with coronary artery disease.
Journal ArticleDOI
Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans
Michael S. Roberts,Michael S. Roberts,Derek Driggs,Matthew Thorpe,Julian D. Gilbey,Michael Yeung,Stephan Ursprung,Angelica I. Aviles-Rivero,Christian Etmann,Cathal McCague,Lucian Beer,Jonathan R. Weir-McCall,Jonathan R. Weir-McCall,Zhongzhao Teng,Effrossyni Gkrania-Klotsas,James H.F. Rudd,Evis Sala,Carola-Bibiane Schönlieb +17 more
TL;DR: It is found that none of the models identified are of potential clinical use due to methodological flaws and/or underlying biases, which is a major weakness, given the urgency with which validated COVID-19 models are needed.
Journal ArticleDOI
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
Zahi A. Fayad,Venkatesh Mani,Mark Woodward,David Kallend,Markus Abt,Tracy Burgess,Valentin Fuster,Valentin Fuster,Christie M. Ballantyne,Evan A. Stein,Jean-Claude Tardif,James H.F. Rudd,Michael E. Farkouh,Michael E. Farkouh,Ahmed Tawakol +14 more
TL;DR: al-PLAQUE as discussed by the authors is the first multicentre study using novel non-invasive multimodal imaging to assess structural and inflammatory indices of atherosclerosis as primary endpoints.
Journal ArticleDOI
Coronary Arterial 18F-Sodium Fluoride Uptake : A Novel Marker of Plaque Biology
Marc R. Dweck,Marcus W. L. Chow,N Joshi,Michelle C. Williams,Charlotte Jones,Alison Fletcher,Hamish Richardson,A. White,Graham McKillop,Edwin Jacques Rudolph van Beek,Nicholas A. Boon,James H.F. Rudd,David E. Newby +12 more
TL;DR: 18F-NaF is a promising new approach for the assessment of coronary artery plaque biology and prospective studies with clinical outcomes are now needed to assess whether coronary 18F- NaF uptake represents a novel marker of plaque vulnerability, recent plaque rupture, and future cardiovascular risk.